RBR-29x8qk进行中（未招募）未知
Safety, Feasibility and Cardiovascular Benefits of a Home-Based Exercise Program in Patients with Sickle Cell Disease
Faculdade de Medicina de Botucatu da Universidade Estadual Paulista Júlio de Mesquita Filho0 个研究点开始时间: 2020年6月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 70Y（—）
入选标准
- •Patients with sickle cell disease; over 18 year, with no sickle cell crise at least 30 days before the beginning of the exercise protocol; who agreed to participate in the study and signed an informed consent form.
排除标准
- •Patients who did not agree to participate in the study.
研究者
相似试验
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ROovo Nordisk A/S3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ITOVO NORDISK. S.P.A.3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-GBovo Nordisk A/S3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-NLovo Nordisk A/S3,176
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesMedDRA version: 19.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2015-003563-10-ESovo Nordisk A/S3,176